Achieve Life Sciences Inc Dossier
Qualitative Analysis
Business overview
Achieve Life Sciences, Inc. (NASDAQ: ACHV) is a late-stage clinical specialty pharmaceutical company dedicated to addressing the global nicotine addiction and smoking health epidemic. The company's primary focus is the development and commercialization of cytisinicline, a plant-based alkaloid designed to interact with nicotine receptors in the brain to reduce the severity of nicotine withdrawal symptoms. Cytisinicline aims to become the first new FDA-approved prescription treatment for nicotine dependence in over two decades, targeting both combustible cigarette smoking and e-cigarette vaping cessation. Achieve operates primarily in the United States, Canada, and the United Kingdom.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning the commercial strength drug product manufacturing of cytisinicline to Adare Pharma Solutions in the United States.
Expected impact: Provides a robust domestic supply chain and resolves regulatory hurdles associated with the prior European manufacturer's cGMP observations.
Advancing cytisinicline for e-cigarette and vaping cessation, supported by the FDA's Breakthrough Therapy Designation and the Commissioner's National Priority Voucher.
Expected impact: Positions cytisinicline to potentially become the first FDA-approved prescription pharmacotherapy specifically targeted at combating e-cigarette addiction.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Critical partnership to establish a U.S.-based manufacturing source for cytisinicline, addressing FDA concerns and securing commercial supply.
Terms: We expect to incur approximately $3.2 million in expenses over the term of the Adare Agreements.